Kura Oncology has been granted a patent for methods of treating hematological malignancies and Ewings sarcoma using menin inhibitors. The patent also includes compositions for these treatments. GlobalData’s report on Kura Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Kura Oncology, Cancer treatment biomarkers was a key innovation area identified from patents. Kura Oncology's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Treating leukemia with menin inhibitors
A recently granted patent (Publication Number: US11944627B2) discloses a method for treating acute myeloid leukemia or acute lymphoblastic leukemia in a subject by administering a menin inhibitor. The method involves targeting subjects with elevated myeloid ecotropic viral integration site 1 (MEIS1) expression levels and utilizing a specific compound (Formula I-B-1) as the menin inhibitor. The administration of this inhibitor aims to reduce the expression of a target gene, particularly Meis1, in individuals with specific genetic mutations or gene rearrangements commonly associated with these types of leukemia.
The patent claims further specify the genetic profiles of subjects who could benefit from this treatment, including those with nucleoporin 98 (NUP98) gene fusion, mutations in genes like nucleophosmin (NPM1), DNA (cytosine-5)-methyltransferase 3A (DNMT3A), FMS-like tyrosine kinase-3 (FLT3), isocitrate dehydrogenase 1 (IDH1), and isocitrate dehydrogenase 2 (IDH2), as well as mixed lineage leukemia (MLL) gene amplification, rearrangement, or partial tandem duplication. The compound of Formula (I-B-1) or its pharmaceutically acceptable salt, as described in the patent, is crucial for the efficacy of this method. The patent provides a detailed framework for the administration of the menin inhibitor and the specific genetic contexts in which this treatment can be beneficial for individuals with acute myeloid leukemia or acute lymphoblastic leukemia.
To know more about GlobalData’s detailed insights on Kura Oncology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
